Stockscreener 앱 받기
5.85
7.54%
0.41
시간 외 거래:
5.87
0.02
+0.34%
전일 마감가:
$5.44
열려 있는:
$5.48
하루 거래량:
3.19M
Relative Volume:
1.38
시가총액:
$1.05B
수익:
$850.00K
순이익/손실:
$-66.49M
주가수익비율:
-13.49
EPS:
-0.4336
순현금흐름:
$-49.17M
1주 성능:
+8.33%
1개월 성능:
+12.72%
6개월 성능:
+22.64%
1년 성능:
+244.12%
1일 변동 폭
$5.38
$5.92
1주일 범위
$5.00
$5.92
52주 변동 폭
$1.60
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
명칭
Compass Therapeutics Inc
전화
617-500-8099
주소
80 GUEST STREET, BOSTON
Compare CMPX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
5.85 | 979.68M | 850.00K | -66.49M | -49.17M | -0.4336 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-13 | 개시 | Craig Hallum | Buy |
| 2026-01-05 | 개시 | William Blair | Outperform |
| 2025-12-03 | 개시 | Canaccord Genuity | Buy |
| 2025-12-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-03 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-07-01 | 재개 | Raymond James | Outperform |
| 2025-04-02 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | 개시 | Guggenheim | Buy |
| 2025-02-19 | 개시 | Piper Sandler | Overweight |
| 2024-12-23 | 개시 | D. Boral Capital | Buy |
| 2024-11-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | 개시 | Jefferies | Buy |
| 2023-01-27 | 개시 | Stifel | Buy |
| 2022-05-23 | 재개 | H.C. Wainwright | Buy |
| 2022-03-15 | 개시 | Ladenburg Thalmann | Buy |
| 2022-01-19 | 개시 | B. Riley Securities | Buy |
| 2021-12-22 | 개시 | Raymond James | Outperform |
| 2021-12-20 | 개시 | SVB Leerink | Outperform |
| 2021-12-15 | 개시 | Wedbush | Outperform |
모두보기
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
CMPX Forecast, Price Target & Analyst Ratings | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Guardant Health (GH) and Compass Therapeutics (CMPX) - The Globe and Mail
CCORF Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Strong Analyst Confidence in Compass Therapeutics (CMPX) Driven by CTX-10726 Advancement - MSN
Portfolio Recap: Why is Compass Therapeutics Inc stock going downQuarterly Investment Review & Low Risk Growth Stock Ideas - baoquankhu1.vn
CMPX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Compass Therapeutics Inc. (CMPX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX) - The Globe and Mail
Traders Buy High Volume of Compass Therapeutics Call Options (NASDAQ:CMPX) - MarketBeat
Stifel reiterates Compass Therapeutics stock rating ahead of trial data By Investing.com - Investing.com Canada
Stifel reiterates Compass Therapeutics stock rating ahead of trial data - Investing.com
Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
CMPX Stock Price, Quote & Chart | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Fundamentals Check: Why is Compass Therapeutics Inc stock going downTrade Risk Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
CMPX Technical Analysis | Trend, Signals & Chart Patterns | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Compass Therapeutics (CMPX) Receives a Buy from Guggenheim - The Globe and Mail
Compass Therapeutics (NASDAQ:CMPX) Given “Buy” Rating at Guggenheim - Defense World
Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from Guggenheim - MarketBeat
Compass Therapeutics: Potential Here, But Patience Required (NASDAQ:CMPX) - Seeking Alpha
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will Compass Therapeutics Inc stock go up in YEARWeekly Trade Summary & Fast Moving Market Watchlists - baoquankhu1.vn
Compass Therapeutics, Inc.Common Stock (NQ: CMPX - The Chronicle-Journal
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing - AOL.com
Here's why Compass Therapeutics, Inc. (CMPX) is a great momentum stock to buy - MSN
Compass Therapeutics Sees Major Institutional Investment Boost - National Today
Compass Therapeutics, Inc. $CMPX Stock Position Lifted by Suvretta Capital Management LLC - MarketBeat
Cantor Fitzgerald Maintains Overweight on CMPX (Compass Therapeutics, Inc.), Mar 2026 - Meyka
Is Compass Therapeutics' (CMPX) New ESOP Shelf Offering Reframing Its Equity-Funded R&D Strategy? - simplywall.st
Compass Therapeutics Inc celebrates women leadership driving innovation in science and therapy development - Traders Union
Compass Therapeutics stock rating reaffirmed at Citizens on trial progress By Investing.com - Investing.com Canada
What Compass Therapeutics (CMPX)'s Pipeline Progress And 2025 Losses Reveal About Its Oncology Strategy - Yahoo Finance
HC Wainwright Has Positive Estimate for CMPX FY2026 Earnings - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Silence Therapeutics (SLN), RxSight (RXST) and Compass Therapeutics (CMPX) - The Globe and Mail
What is HC Wainwright's Estimate for CMPX Q1 Earnings? - MarketBeat
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update - Sahm
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Jefferies raises Compass Therapeutics stock price target on trial progress By Investing.com - Investing.com Australia
Jefferies raises Compass Therapeutics stock price target on trial progress - Investing.com
Compass Therapeutics stock holds Outperform at William Blair ahead of trial data - Investing.com Canada
Raymond James reiterates Compass Therapeutics stock Outperform rating By Investing.com - Investing.com Canada
Raymond James reiterates Compass Therapeutics stock Outperform rating - Investing.com
Compass Therapeutics (NASDAQ:CMPX) Releases Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Compass Therapeutics Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Compass Therapeutics' Q4 Net Loss Narrows - marketscreener.com
Earnings Flash (CMPX) Compass Therapeutics Posts Q4 Net Loss $0.09 a Share, vs. FactSet Est of $0.09 Loss - marketscreener.com
Compass Therapeutics' 2025 net loss widens as R&D costs jump - TradingView
Compass Therapeutics 10-K: $0.0M Revenue, $(0.42) EPS on $(66.5)M Net Loss - TradingView
How Palo Alto’s New Stake and Rising Institutional Ownership At Compass Therapeutics (CMPX) Has Changed Its Investment Story - simplywall.st
Assessing Compass Therapeutics (CMPX) Valuation As CTX-009 Gains Attention In Biliary Tract Cancer Market - Yahoo Finance
Compass Therapeutics Inc (CMPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):